UCB (OTCMKTS:UCBJF) and BioDelivery Sciences International (NASDAQ:BDSI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.
Institutional and Insider Ownership
69.4% of BioDelivery Sciences International shares are held by institutional investors. 8.9% of BioDelivery Sciences International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current ratings for UCB and BioDelivery Sciences International, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BioDelivery Sciences International||0||0||6||0||3.00|
BioDelivery Sciences International has a consensus target price of $6.80, suggesting a potential upside of 5.26%. Given BioDelivery Sciences International’s higher possible upside, analysts clearly believe BioDelivery Sciences International is more favorable than UCB.
This table compares UCB and BioDelivery Sciences International’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BioDelivery Sciences International||-22.11%||-8.80%||-3.02%|
Volatility and Risk
UCB has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, BioDelivery Sciences International has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Earnings and Valuation
This table compares UCB and BioDelivery Sciences International’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|UCB||$4.55 billion||3.40||$575.43 million||N/A||N/A|
|BioDelivery Sciences International||$55.64 million||10.39||-$33.87 million||($0.73)||-8.85|
UCB has higher revenue and earnings than BioDelivery Sciences International.
UCB beats BioDelivery Sciences International on 6 of the 11 factors compared between the two stocks.
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer. The company also develops buprenorphine extended release injection, an injectable microparticle formulation of buprenorphine for the treatment of opioid dependence and chronic pain. BioDelivery Sciences International, Inc. has a licensing and development agreement with Evonik Corporation and Meda AB. The company was founded in 1997 and is headquartered in Raleigh, North Carolina.
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.